Lijun Li , Mengran Guo , Zhangyu Wang , Mingxuan Yu , Dian Cai , Yuqi Xu , Zhi Liu , Can Huang , Zhaohui Jin , Yongmei Xie , Xiangrong Song , Xinxin Zhang
{"title":"Lipid-based nanosystems for atherosclerosis treatment: Evolving approaches and novel therapeutic strategies","authors":"Lijun Li , Mengran Guo , Zhangyu Wang , Mingxuan Yu , Dian Cai , Yuqi Xu , Zhi Liu , Can Huang , Zhaohui Jin , Yongmei Xie , Xiangrong Song , Xinxin Zhang","doi":"10.1016/j.apsb.2025.11.001","DOIUrl":null,"url":null,"abstract":"<div><div>Atherosclerosis, the leading cause of cardiovascular diseases, has become increasingly prevalent worldwide, driving the need for innovative therapeutic strategies to improve clinical outcomes. Lipid-based nanosystems have emerged as promising drug delivery platforms due to their biocompatibility, versatility, and proven clinical track records. Among them, traditional systems such as liposomes have been extensively applied in atherosclerosis therapy, primarily for their well-established safety profile and their capacity to deliver both hydrophilic and hydrophobic agents. However, emerging research has expanded the scope of lipid-based nanosystems to include lipid nanoparticles, lipoprotein-based nanosystems, cell membrane-coated nanosystems, and so on. These systems have demonstrated great promise in addressing the complex and heterogeneous nature of the disease. This review aims to provide a comprehensive overview of lipid-based nanosystems, from traditional formulations to cutting-edge innovations, and their evolving applications in the treatment of atherosclerosis. We also discuss the challenges associated with the clinical translation of these systems, as well as future prospects for developing more effective and personalized therapeutic strategies. In conclusion, lipid-based nanosystems provide a promising option for atherosclerosis treatment, potentially driving the progress of novel therapeutic strategies.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 4","pages":"Pages 2153-2173"},"PeriodicalIF":14.6000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmaceutica Sinica. B","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211383525007312","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Atherosclerosis, the leading cause of cardiovascular diseases, has become increasingly prevalent worldwide, driving the need for innovative therapeutic strategies to improve clinical outcomes. Lipid-based nanosystems have emerged as promising drug delivery platforms due to their biocompatibility, versatility, and proven clinical track records. Among them, traditional systems such as liposomes have been extensively applied in atherosclerosis therapy, primarily for their well-established safety profile and their capacity to deliver both hydrophilic and hydrophobic agents. However, emerging research has expanded the scope of lipid-based nanosystems to include lipid nanoparticles, lipoprotein-based nanosystems, cell membrane-coated nanosystems, and so on. These systems have demonstrated great promise in addressing the complex and heterogeneous nature of the disease. This review aims to provide a comprehensive overview of lipid-based nanosystems, from traditional formulations to cutting-edge innovations, and their evolving applications in the treatment of atherosclerosis. We also discuss the challenges associated with the clinical translation of these systems, as well as future prospects for developing more effective and personalized therapeutic strategies. In conclusion, lipid-based nanosystems provide a promising option for atherosclerosis treatment, potentially driving the progress of novel therapeutic strategies.
Acta Pharmaceutica Sinica. BPharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
CiteScore
22.40
自引率
5.50%
发文量
1051
审稿时长
19 weeks
期刊介绍:
The Journal of the Institute of Materia Medica, Chinese Academy of Medical Sciences, and the Chinese Pharmaceutical Association oversees the peer review process for Acta Pharmaceutica Sinica. B (APSB).
Published monthly in English, APSB is dedicated to disseminating significant original research articles, rapid communications, and high-quality reviews that highlight recent advances across various pharmaceutical sciences domains. These encompass pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis, and pharmacokinetics.
A part of the Acta Pharmaceutica Sinica series, established in 1953 and indexed in prominent databases like Chemical Abstracts, Index Medicus, SciFinder Scholar, Biological Abstracts, International Pharmaceutical Abstracts, Cambridge Scientific Abstracts, and Current Bibliography on Science and Technology, APSB is sponsored by the Institute of Materia Medica, Chinese Academy of Medical Sciences, and the Chinese Pharmaceutical Association. Its production and hosting are facilitated by Elsevier B.V. This collaborative effort ensures APSB's commitment to delivering valuable contributions to the pharmaceutical sciences community.